Loading...
Market
Which cancer type will be the next major indication for AstraZeneca's Imfinzi by end of 2025?
2
Resolution / Starting Odds
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%
Clinical trial results published in medical journals or announced at conferences
Story
AstraZeneca's Imfinzi Shows Promise in Bladder Cancer Treatment
Sep 15, 2024, 02:35 PM
AstraZeneca's Imfinzi (durvalumab) has shown promising results in treating muscle-invasive bladder cancer. In the NIAGARA Phase III trial, the perioperative regimen of Imfinzi reduced the risk of recurrence by 32% and the risk of death by 25% compared to neoadjuvant chemotherapy alone. These findings suggest that Imfinzi could potentially extend the lives of bladder cancer patients and open up a new market for the blockbuster medicine. The study's results were highlighted at the ESMO 2024 conference.
View original story
Similar markets
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
NTRK gene fusion cancers • 25%
RET fusion-positive cancers • 25%
Both equally • 25%
Neither • 25%
Tecentriq Hybreza gains the most market share • 25%
Keytruda gains the most market share • 25%
Opdivo gains the most market share • 25%
Other treatment gains the most market share • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
AstraZeneca/Daiichi Sankyo • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Brain cancer • 25%
Breast cancer • 25%
Lung cancer • 25%
Other • 25%